Belgium boy becomes worlds first to beat deadly brain cancer
Lucas Jemeljanova was first diagnosed deadly brain cancer known as diffuse intrinsic pontine glioma (DIPG) at age of six
Lucas Jemeljanova, a 13-year-old boy from Belgium, has accomplished a remarkable feat by becoming the first person in the world to beat a deadly brain cancer known as diffuse intrinsic pontine glioma (DIPG), The Brighter Side reported.
Lucas was first diagnosed with the deadly illness at the age of six. DIPG is a very rare type of brain cancer that statistically kills 98% of patients within five years.
Children with the brain tumour would normally be expected to live nine to 12 months after diagnosis.
Lucas's road to recovery started when he participated in a clinical trial investigating the use of everolimus, a chemotherapeutic medication that is often used to treat brain, kidney, pancreatic, and other malignancies but has not been effectively used to treat DIPG.
Lucas responded well to the treatment, and he saw the tumour gradually go away.
After five years of declared remission, he has now been cancer-free for the last seven years.
At the Gustave Roussy cancer centre in Paris, his doctor Dr Jacques Grill, expressed happiness yet shock at his recovery, saying, "Lucas beat all the odds... his case offers real hope."
It remains unclear why Lucas recovered from the cancer, and scientists are now looking at how his case can help others with the illness in the future.
In the trial, seven other children survived years after their diagnosis, but only Lucas saw his tumour disappear.
-
Gene mutation may affect how schizophrenia patients see reality
-
Is all chocolate healthy? Here’s what the science really says
-
What to know before using weight-loss drugs like Ozempic
-
Singapore confirms first local spread of mutated monkeypox clade Ib strain
-
World Autism Awareness Day: Celebrating different minds, shaping a shared future
-
Some grief never goes away—Scientists now know why
-
E-cigarettes: A proving quitting tool that still carries health risks
-
Eli Lilly expands $2.75B AI-enabled drug discovery deal with Insilico Medicine